Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-27T09:44:24.296Z Has data issue: false hasContentIssue false
  • English
  • Français

The Use of Natalizumab for Treatment of MS: Do the Risks Still Outweigh the Gains?

Published online by Cambridge University Press:  02 December 2014

Mark Freedman
Mark Freedman*
Affiliation:
The Ottawa Hospital, Ottawa, Ontario, Canada
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorial
Information
Canadian Journal of Neurological Sciences , Volume 39 , Issue 5 , September 2012 , pp. 559 - 560
Copyright
Copyright © The Canadian Journal of Neurological 2012

References

1.Goodin, DS, Reder, AT, Ebers, GC, et al.Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNbeta-1b trial. Neurology. 2012;78(17):1315–22.Google Scholar
2.O’Connor, P.Natalizumab risk stratification: role of a two-step anti-JCV antibody assay. Can J Neurol Sci. 2012;39(5):670–5.Google Scholar
3.Miravalle, A, Jensen, R, Kinkel, RP.Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol. 2011; 68(2):186–91.Google Scholar
4.Goodin, DS.Disease-modifying therapy in multiple sclerosis: update and clinical implications. Neurology. 2008;71(24 Suppl 3):S8–13.Google Scholar
5.Havrdova, E, Galetta, S, Hutchinson, M, et al.Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8(3):254–60.Google Scholar
6.Freedman, MS.Multiple Sclerosis therapeutic strategies: use second line agents as first-line agents when time is of the essence.. Neurol Clin Prac. 2011;1(1):66–8.Google Scholar